Clinical trial · Interventional
A Study to Assess the Efficacy of Intravenous/Oral Bondronat (Ibandronate) in Patients With Metastatic Bone Disease Experiencing Moderate to Severe Pain
A Randomized, Double-blind Study of the Effect of Bondronat Compared With Zoledronic Acid on Pain in Patients With Malignant Bone Disease Experiencing Moderate to Severe Pain
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This 2 arm study will compare the efficacy of a regimen of intravenous (iv) and oral Bondronat with that of zoledronic acid in patients with malignant bone disease experiencing moderate to severe pain. Patients will be randomized to receive either Bondronat (6mg iv on days 1, 2 and 3 followed by Bondronat 5Omg po daily from day 22 to week 24) or zoledronic acid (4mg iv on day 1, and then every 3-4 weeks). The anticipated time of study treatment is 6-12 months, and the target sample size is 100-500 individuals.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bone Neoplasm | Bone Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Neoplasm Metastasis | — | UNRESOLVED | — |
| Pain | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ibandronate [Bondronat] | Drug | Ibandronic Acid | ALIAS |
| zoledronic acid | Drug | Zoledronic Acid | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- 1
- interventionNames
- Drug: ibandronate [Bondronat]
- type
- ACTIVE_COMPARATOR
- label
- 2
- interventionNames
- Drug: zoledronic acid
Primary outcomes (1)
- measure
- Pain, as measured by Brief Pain Inventory and analgesic use
- timeFrame
- Week 24
Secondary outcomes (4)
- measure
- Performance score and QoL measures
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * patients with malignant bone disease; * patients with moderate to severe pain. Exclusion Criteria: * patients who have received a bisphosphonate within 3 weeks from the signing of informed consent; * patients receiving concurrent investigational therapy, or who have received investigational therapy within 30 days of the first scheduled day of dosing; * untreated esophagitis or gastric ulcers; * recent or pre-scheduled radiotherapy to bone; * patients who are pregnant or breast-feeding.
References
Publications (0)
Data not yet available